AAM
EIDX

Alpine Associates Management’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Alpine Associates Management’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-184,221
Closed -$24.2M – 62
2020
Q4 		$24.2M Buy
+184,221
New +$16.3M 0.99% 24

Alpine Associates Management's EIDX Position: Q1 2021 in Review

Alpine Associates Management sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 184,221 shares — an estimated $24.2M sold.

Alpine Associates Management first reported a position in EIDX in Q4 2020 and held it in 1 quarter. The position peaked at $24.2M in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

  • Alpine Associates Management reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Alpine Associates Management sold 184,221 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $24.2M.
  • Alpine Associates Management first reported a position in Eidos Therapeutics, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • Alpine Associates Management's Eidos Therapeutics, Inc. Common Stock position peaked at $24.2M in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Alpine Associates Management's 13F filing for Q1 2021, filed 11 May 2021.